Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials

Rapid response to vedolizumab therapy in biologic-naïve patients with inflammatory bowel diseases

(2018) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis—a Systematic Review and Meta-Analysis

(2018) Neeraj Narula et al.   Clinical Gastroenterology and Hepatology

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

(2017) Fernando Magro et al.   Journal of Crohns & Colitis

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis

(2015) Sanjay K. Murthy et al.   INFLAMMATORY BOWEL DISEASES

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2 and 3

(2014) Jean-Frederic Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Multipotent role of platelets in inflammatory bowel diseases: A clinical approach

(2014) Evangelos Voudoukis   WORLD JOURNAL OF GASTROENTEROLOGY

Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

European consensus on the histopathology of inflammatory bowel disease

(2013) F. Magro et al.   Journal of Crohns & Colitis

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

(2012) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis

(2012) Cemal Bes et al.   RHEUMATOLOGY INTERNATIONAL

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-  treatment

(2009) G. Bergamaschi et al.   HAEMATOLOGICA

Anemia and inflammatory bowel diseases

(2009) Fernando Gomollón et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis